Choose your location
Select your country or region to view content specific to your country.
Product News You can check out the latest product information
-
Obtained CE-IVD marking for Magicplex™ STI1 (MMU) Real-time Test
Magicplex™ STI1 Real-time Test1Detection of 5 most common STI pathogens Seegene's Magicplex™ STI1 (MMU) Real-time Test has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.
Oct 21, 2010｜ Magicplex STI1 (MMU) Real-time Test
-
Obtained CE-IVD marking for Magicplex™ VanR Real-time Test
Magicplex™ VanR Real-time TestSimultaneous detection of vanA, vanB, and vanC genes Seegene's Magicplex™ VanR Real-time Test has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.
Oct 15, 2010｜ Magicplex VanR Real-Time Test
-
Obtained CE-IVD marking for Anyplex™ BRAF V600E Real-time Detection
Anyplex™ BRAF V600E Real-time DetectionDetection of BRAF V600E Mutation Seegene's Anyplex™ BRAF V600E Real-time Detection?has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.
Sep 24, 2010｜ Anyplex™ BRAF V600E Real-time Detection
-
Obtained CE-IVD marking for Magicplex™ MTB Real-time Test
Detection of Mycobacterium tuberculosis Seegene's Magicplex™ MTB Real-time Test has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.
Aug 16, 2010｜ Magicplex MTB Real-Time Test
-
Launched Anyplex™ BRAF V600E Real-time Detection
Anyplex™ BRAF V600E Real-time DetectionAnyplex™ BRAF V600E Real-time Detection is designed to detect BRAF mutation (V600E) characteristic for papillary thyroid carcinoma from samples of thyroid tissue, FNAB, H&E slides and paraffin-embedded tissues. The BRAF gene involves in mediating cellular response to growth, differentiation and death signals in RAS → RAF → MEK → MAP kinase pathway. BRAF mutations are common in melanoma, colon cancer, gliomas, and lung cancer. In 80% cases, it is a single substitution1), 2) (V600E). Especially, in papillary thyroid carcinoma (PTC), the incidence of BRAF mutation occurs 26 ? 69% (likely 45-50%) of all cases1), 3). Anyplex™ BRAF V600E Real-time Detection tests BRAF mutation, the most common genetic mutation in PTC, with single PCR reaction by utilizing DPO™ technology. 1) M Xing. BRAF mutation in thyroid cancer, Endocrine-Related Cancer, 2005, 12, 245-262. 2) Wojciechowska K andLewinski A: BRAF Mutations in Papillary Thyroid Carcinoma, Endocrine Regulations, 2006, 40, 129-138. 3) Ki-wook Chung et al. Clinical Endocrinology, 2006, 65, 660-666.
Aug 13, 2010｜ Anyplex™ BRAF V600E Real-time Detection
-
Obtained CE-IVD marking for Seeplex® STD 4D ACE Detection
Simultaneously detecting 4 different STD pathogensSeegene's Seeplex® STD 4D ACE Detection has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.
Jul 28, 2010｜ Seeplex® STD 4D ACE Detection
-
Obtained Medical Device License By Health Canada : Seeplex® RV15 ACE Detection
Simultaneously detecting 15 major respiratory viruses Obtained Medical Device License By Health Canada : Seeplex® RV15 ACE Detection
Jul 23, 2010｜ Seeplex® RV15 ACE Detection
-
Obtained Medical Device License By Health Canada : Seeplex® RV15 OneStep ACE Detection
Simultaneously detecting 15 major respiratory viruses Obtained Medical Device License By Health Canada : Seeplex® RV15 OneStep ACE Detection1
Jul 23, 2010｜ Seeplex® RV15 OneStep ACE Detection